Variables significantly related to adverse outcome: univariate Cox analyses
| Univariate analysis | Adverse clinical event (n=107) (49%) | No adverse clinical event (n=102) (51%) | Exp (β) | CI | p Value |
| Brachial systolic blood pressure (mm Hg) | 130±15 | 138±16 | 0.98 | 0.96 to 0.99 | <0.001 |
| Diabetes mellitus | 10% | 2% | 4.31 | 2.26 to 8.20 | <0.001 |
| Transaortic valve peak gradient (mm Hg) | 66±26 | 56±19 | 1.02 | 1.01 to 1.03 | <0.001 |
| Aortic valve area (cm2/m2) | 0.46±0.1 | 0.52±0.1 | 0.01 | 0.008 to 0.04 | <0.001 |
| Energy loss index (cm2/m2) | 0.38±0.11 | 0.57±0.10 | 0.01 | 0.004 to 0.14 | <0.001 |
| Stroke work loss (%) | 24.6±7.4 | 21.7±6.5 | 1.06 | 1.03 to 1.09 | <0.001 |
| Valvulo-arterial impedance (mmHg/ml/m2.04) | 6.5±2.5 | 6.2±1.9 | 0.99 | 0.88 to 1.12 | 0.92 |
| Relative wall thickness | 0.50±0.1 | 0.47±0.1 | 1.03 | 1.01 to 1.05 | <0.001 |
| LVM (g/m2.7) LVH | 66±21 79% | 56±15 70% | 1.03 1.78 | 1.01 to 1.04 1.11 to 2.85 | <0.001 0.02 |
| Aortic valve calcifications (score 1–4) Aortic valve calcification (score 4 vs others) | 3.7±0.6 71% | 3.2±0.7 30% | 2.00 2.24 | 1.24 to 3.23 1.23 to 2.08 | 0.004 0.008 |
| Stress-corrected midwall shortening (%) | 73±15 | 83±16 | 0.98 | 0.97 to 0.99 | 0.03 |
| LV mass as % of predicted (%) Inappropriately high LVM | 133±38 76% | 113±29 42% | 1.01 2.93 | 1.00 to 1.01 1.88 to 4.56 | 0.02 <0.001 |
| Female gender | 60% | 62% | 0.98 | 0.66 to 1.46 | 0.94 |
| Age (years) | 75±11 | 75±10 | 1.01 | 0.99 to 1.02 | 0.32 |
| History of hypertension | 54% | 55% | 1.11 | 0.64 to 1.79 | 0.60 |
LVH, left ventricular hypertrophy; LVM, left ventricular mass.